JSPR
Jasper Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$0.71
+3.23%Price chart
Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−0.5x
Market Cap
$23.58M
MomentumView details →
1D Return
+3.23%
YTD Return
−62.70%
RSI (14)
46.2
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−0.5x
Market Cap
$23.58M
RSI (14)
46.2
MomentumView details →
1D Return
+3.23%
YTD Return
−62.70%
SummaryUpdated Jun 1, 2026
Jasper Therapeutics, Inc. (NASDAQ:JSPR) is a clinical-stage biotechnology company founded in 2020 and based in Redwood City, California. The company specializes in developing innovative therapeutic agents for hematopoietic stem cell transplantation and gene therapies, with a focus on conditioning agents and stem cell engineering technologies. Since going public in January 2020, Jasper has been advancing its pipeline of experimental treatments designed to expand the use of stem cell transplantation and improve outcomes for patients requiring these life-saving procedures.
Similar companies
Latest newsMore news →
Jasper Therapeutics reported a net loss of $2.76 million for Q2 2026, with diluted loss per share of $0.10, and cash and cash equivalents of $7.3 million as of June 30, 2026.22d agoJasper Therapeutics raised $132 million in a private stock offering.50d agoJasper Therapeutics acquired Kira Pharmaceuticals via a reverse triangular merger, with consideration of Jasper common and convertible preferred stock.50d ago